JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model

Blood

Volumn 108, Issue 8, 2006, Pages 2770-2779

  Mercher, Thomas ^b   Wernig, Gerlinde ^b   Moore, Sandra A ^b   Levine, Ross L ^b   Gu, Ting Lei ^b   Fröhling, Stefan ^b   Cullen, Dana ^b   Polakiewicz, Roberto D ^b   Bernard, Olivier A ^b   Boggon, Titus J ^b   Lee, Benjamin H ^b   Gilliland, D Gary ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PROTEIN TYROSINE KINASE INHIBITOR; STAT5 PROTEIN; TYROSINE; JAK2 PROTEIN, HUMAN; JAK2 PROTEIN, MOUSE; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MASS SPECTROMETRY; MEGAKARYOCYTE; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ACUTE NONLYMPHOCYTIC LEUKEMIA; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL DIFFERENTIATION; CELL STRAIN K 562; CHEMICAL STRUCTURE; CHEMISTRY; CLONOGENIC ASSAY; ENZYME ACTIVATION; ENZYMOLOGY; GENETIC TRANSDUCTION; GENETICS; IMMUNOPHENOTYPING; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; PROTEIN CONFORMATION; TUMOR CELL LINE;

ANIMALS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL LINE, TUMOR; COLONY-FORMING UNITS ASSAY; ENZYME ACTIVATION; HUMANS; IMMUNOPHENOTYPING; JANUS KINASE 2; K562 CELLS; LEUKEMIA, MEGAKARYOCYTIC, ACUTE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, MOLECULAR; MUTATION; MYELOPROLIFERATIVE DISORDERS; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; STAT5 TRANSCRIPTION FACTOR; TRANSDUCTION, GENETIC;

EID: 33750627651     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-04-014712     Document Type: Article

References (49)

1. Lion T, Haas OA, Harbott J, et al. The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children. Blood. 1992;79:3325-3330.
2. Dastugue N, Lafage-Pochitaloff M, Pages MP, et al. Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood 2002;100:618-626.
3. Paredes-Aguilera R, Romero-Guzman L, Lopez-Santiago N, Trejo RA. Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children. Am J Hematol. 2003;73:71-80.
4. Akahoshi M, Oshimi K, Mizoguchi H, Okada M, Enomoto Y, Watanabe Y. Myeloproliferative disorders terminating in acute megakaryoblastic leukemia with chromosome 3q26 abnormality. Cancer. 1987;60:2654-2661.
5. Ohyashiki K, Ohyashiki JH, Hojo H, et al. Cytogenetic findings in adult acute leukemia and myeloproliferative disorders with an involvement of megakaryocyte lineage. Cancer. 1990;65:940-948.
6. Radaelli F, Mazza R, Curioni E, Ciani A, Pomati M, Maiolo AT. Acute megakaryocytic leukemia in essential thrombocythemia: an unusual evolution? Eur J Haematol. 2002;69:108-111.
7. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105:973-977.
8. Duchayne E, Fenneteau O, Pages MP, et al. Acute megakaryoblastic leukaemia: a national clinical and biological study of 53 adult and childhood cases by the Groupe Francais d'Hematologie Cellulaire (GFHC). Leuk Lymphoma. 2003;44:49-58.
9. Nimer SD, MacGrogan D, Jhanwar S, Alvarez S. Chromosome 19 abnormalities are commonly seen in AML, M7. Blood. 2002;100:3838; author reply 3838-3839.
10. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148-152.
11. Ma Z, Morris SW, Valentine V, et al. Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet. 2001;28:220-221.
12. Mercher T, Coniat MB, Monni R, et al. Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. Proc Natl Acad Sci U S A. 2001;98:5776-5779.
13. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review. Pediatr Hematol Oncol. 1992;9:139-149.
14. Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 2004;103:399-406.
15. Crispino JD, Taub JW, Mundschau G, et al. GATA1 in normal and malignant hematopoiesis. Semin Cell Dev Biol. 2005;16:137-147.
16. Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005;37:613-619.
17. Ng KC, Tan AM, Chong YY, Lau LC, Lou J. Congenital acute megakaryoblastic leukemia (M7) with chromosomal t(1;22)(p13;q13) translocation in a set of identical twins. J Pediatr Hematol Oncol. 1999;21:428-430.
18. Gouilleux-Gruart V, Gouilleux F, Desaint C, et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood. 1996;87:1692-1697.
19. Spiekermann K, Biethahn S, Wilde S, Hiddemann W, Alves F. Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol. 2001;67:63-71.
20. Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood. 2003;101:2940-2954.
21. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2003;19:624-631.
22. Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res. 2003;9:2140-2150.
23. Casteran N, De Sepulveda P, Beslu N, et al. Signal transduction by several KIT juxtamembrane domain mutations. Oncogene. 2003;22:4710-4722.
24. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3:650-665.
25. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999;93:3074-3080.
26. D'Andrea AD, Yoshimura A, Youssoufian H, Zon LI, Koo JW, Lodish HF. The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Mol Cell Biol. 1991;11:1980-1987.
27. Tong W, Lodish HF. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med. 2004;200:569-580.
28. Eder M, Ernst TJ, Ganser A, Jubinsky PT, Inhorn R, Hoelzer D, Griffin JD. A low affinity chimeric human alpha/beta-granulocyte-macrophage colony-stimulating factor receptor induces ligand-dependent proliferation in a murine cell line. J Biol Chem. 1994;269:30173-30180.
29. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;14:14.
30. Cools J, Quentmeier H, Huntly BJ, Marynen P, Griffin JD, Drexler HG, Gilliland DG. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 2004;103:2802-2805.
31. Schwaller J, Frantsve J, Aster J, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 1998;17:5321-5333.
32. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
33. Jones TA, Zou JY, Cowan SW, Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A. 1991;47:110-119.
34. Rush J, Moritz A, Lee KA, et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol. 2005;23:94-101.
35. Lucet IS, Fantino E, Styles M, et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood. 2006;107:176-183.
36. Boggon TJ, Li Y, Manley PW, Eck MJ. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood. 2005;106:996-1002.
37. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
38. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
39. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
40. Lu X, Levine R, Tong W, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A. 2005;102:18962-18967.
41. Vinci G, Tabilio A, Deschamps JF, et al. Immunological study of in vitro maturation of human megakaryocytes. Br J Haematol. 1984;56:589-605.
42. Debili N, Issaad C, Masse JM, et al. Expression of CD34 and platelet glycoproteins during human megakaryocytic differentiation. Blood. 1992;80:3022-3035.
43. Witte DP, Harris RE, Jenski LJ, Lampkin BC. Megakaryoblastic leukemia in an infant: establishment of a megakaryocytic tumor cell line in athymic nude mice. Cancer. 1986;58:238-244.
44. Fugman DA, Witte DP, Jones CL, Aronow BJ, Lieberman MA. In vitro establishment and characterization of a human megakaryoblastic cell line. Blood. 1990;75:1252-1261.
45. Kaushansky K. The enigmatic megakaryocyte gradually reveals its secrets. Bioessays. 1999;21:353-360.
46. + cells are correlated with different levels of platelet release. Blood. 2002;99:888-897.
47. Zhang XF, Wang JF, Matczak E, Proper JA, Groopman JE. Janus kinase 2 is involved in stromal cell-derived factor-1alpha-induced tyrosine phosphorylation of focal adhesion proteins and migration of hematopoietic progenitor cells. Blood. 2001;97:3342-3348.
48. Vila-Coro AJ, Rodriguez-Frade JM, Martin De Ana A, Moreno-Ortiz MC, Martinez AC, Mellado M. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J. 1999;13:1699-1710.
49. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849GT is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370-3373.